BillionToOne Raises 2026 Guidance, Aligns Incentive Plan

The latest announcement is out from BillionToOne, Inc. Class A ( (BLLN) ).

In 2025, BillionToOne doubled total revenue to $305.1 million and turned to profitability, driven by strong growth in prenatal and oncology testing volumes and higher average selling prices. On March 4, 2026, the company reported fourth-quarter revenue of $96.1 million, gross margin of 71%, operating income of $10.3 million, and net income of $4.4 million, while also raising 2026 revenue guidance to $430–$445 million and expecting positive operating income.

Operationally, the company delivered 170,000 tests in the fourth quarter of 2025, a 47% increase year over year, and expanded its portfolio with new prenatal non-invasive fetal antigen tests for HDFN and FNAIT and oncology add-ons Northstar PGx and Northstar Select CH. Also on March 4, 2026, the board approved an annual incentive bonus plan effective January 1, 2026, aligning executive and employee compensation with performance as BillionToOne scales its diagnostics platform and seeks to reinforce talent retention and execution discipline.

The most recent analyst rating on (BLLN) stock is a Buy with a $93.00 price target. To see the full list of analyst forecasts on BillionToOne, Inc. Class A stock, see the BLLN Stock Forecast page.

Spark’s Take on BLLN Stock

According to Spark, TipRanks’ AI Analyst, BLLN is a Neutral.

The score is held down primarily by weak financial performance (ongoing losses and cash burn) and soft technical momentum. These are partially offset by a very strong earnings-call outlook with rapid growth, major margin expansion, and guidance pointing to sustained GAAP operating profitability; valuation remains challenged due to negative earnings and no dividend.

To see Spark’s full report on BLLN stock, click here.

More about BillionToOne, Inc. Class A

BillionToOne, Inc. is a next-generation molecular diagnostics company focused on developing powerful and accurate genetic tests that are accessible to a broad patient population. The company’s core businesses are prenatal and oncology clinical testing, supported by its smNGS technology platform and a growing base of healthcare providers and payers in the U.S. diagnostics market.

In 2025, BillionToOne doubled total revenue to $305.1 million and turned to profitability, driven by strong growth in prenatal and oncology testing volumes and higher average selling prices. On March 4, 2026, the company reported fourth-quarter revenue of $96.1 million, gross margin of 71%, operating income of $10.3 million, and net income of $4.4 million, while also raising 2026 revenue guidance to $430–$445 million and expecting positive operating income.

Operationally, the company delivered 170,000 tests in the fourth quarter of 2025, a 47% increase year over year, and expanded its portfolio with new prenatal non-invasive fetal antigen tests for HDFN and FNAIT and oncology add-ons Northstar PGx and Northstar Select CH. Also on March 4, 2026, the board approved an annual incentive bonus plan effective January 1, 2026, aligning executive and employee compensation with performance as BillionToOne scales its diagnostics platform and seeks to reinforce talent retention and execution discipline.

Average Trading Volume: 232,213

Current Market Cap: $3.81B

For an in-depth examination of BLLN stock, go to TipRanks’ Overview page.